@article{JGO17276,
author = {Matteo Mandrioli and Laura Mastrangelo and Michele Masetti and Nicola Zanini and Stefania Lega and Margherita Nannini and Elisa Gruppioni and Annalisa Altimari and Angelo Paolo Dei Tos and Carlo Fabbri and Elio Jovine},
title = {Characterization of malignant gastrointestinal stromal tumors—a single center experience},
journal = {Journal of Gastrointestinal Oncology},
volume = {8},
number = {6},
year = {2017},
keywords = {},
abstract = {Background: The recurrence rate, related to the unpredictable behavior of gastrointestinal stromal tumors (GISTs), continues to be a major topic of investigation, since no actual risk evaluation scales have proven to be exceedingly effective in predicting prognosis. We therefore focus in this study on investigating the predictive variables of disease recurrence.
Methods: Between September 2004 and January 2011, 34 patients, 18 males and 16 females with a median age of 62 (range, 27–87), underwent operations for primary, localized and advanced GISTs. Immunohistochemical profile, KIT and the platelet-derived growth factor receptor-alpha (PDGFR-α) gene mutations, tumor size, tumor site, mitotic index, synchronous tumors, adjuvant therapy, symptoms and gender were considered and analyzed as predictive variables. The receiver operating characteristic (ROC) analysis was used to determine the optimal cut-off value for tumor dimension to predict recurrence.
Results: The median follow-up (FU) was 20 months (range, 6–86 months). A first-line adjuvant therapy was performed in nine patients. Disease relapse occurred in five cases. The tumor size and the mitotic index were the strongest predictive factors (P},
issn = {2219-679X}, url = {https://jgo.amegroups.org/article/view/17276}
}